Innate Pharma S.A. Sponsored ADR

IPHA Healthcare Biotechnology

Innate Pharma S.A. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $10.2 million, down 53.2% from fiscal 2024.

1.43 0.05 −3.38%
Market cap
$165.3M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
0/9
Altman Z
−11.24
Beneish M
1.14
Dividend safety
n/a
Older periods Dec '24 Jun '25 Dec '25 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
2.60 2.21 1.27 0.60
Net Debt/EBITDA
0.00 0.00 0.00 0.00
Debt/Equity
3.51 5.25 (1.04) (0.50)
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
0.00 0.00 0.00 0.00
Book value per Share
0.00 0.00 0.00 0.00
Free Cash Flow
(7.88) (35.44) (59.85) (24.57)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates